NCT03768336 2026-04-14
A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors
Massachusetts General Hospital
Phase NA Active not recruiting
Clinical Trials
390 trialsNCT05993299 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT04055948 2026-03-30
Building Family Caregiver Skills Using a Simulation-Based Intervention for Care of Cancer Patients
Case Comprehensive Cancer Center
Phase NA Completed
NCT06318338 2026-03-27
Virtual Reality to Promote Relaxation Prior to Simulation
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT02362750 2026-03-25
Evaluating Cancer Survivorship Care Models
George Washington University
Completed
NCT03568058 2026-03-24
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
Phase 1 Completed
NCT03328663 2026-03-20
Psychological Intervention for Caregivers of Patients Undergoing Stem Cell Transplant
Massachusetts General Hospital
Phase NA Completed
NCT06072833 2026-03-16
Characterizing and Addressing Financial Toxicity in AYAs With Cancer
Columbia University
Phase NA Completed
NCT04913259 2026-03-03
TS-PAC
Institut Bergonié
Phase NA Active not recruiting
NCT05148078 2026-03-02
Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT06837090 2026-02-20
SPAINTRK
Grupo Espanol de Tumores Neuroendocrinos
Completed
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT03260023 2026-02-05
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Transgene
Phase 1/2 Active not recruiting
NCT04260529 2026-01-29
CICILIA
Cytovation AS
Phase 1/2 Completed
NCT03436290 2026-01-28
SCOPE
Vanderbilt University Medical Center
Phase NA Active not recruiting
NCT02952248 2026-01-27
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03824158 2026-01-14
Patient-centered and Efficacious Advance Care Planning in Cancer: the PEACe Comparative Effectiveness Trial
University of Pittsburgh
Phase NA Completed
NCT06013176 2025-12-29
BEST-PRO
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT03433898 2025-12-19
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
Boehringer Ingelheim
Phase EARLY_PHASE1 Completed
NCT02275910 2025-12-16
Phase 1 Study of E7090 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT03473652 2025-12-15
APPAHOCA
Centre Francois Baclesse
Phase NA Completed
NCT06347731 2025-12-15
Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan)
Varian, a Siemens Healthineers Company
Phase NA Completed
NCT03676010 2025-12-10
DATECAN-1
Institut Bergonié
Active not recruiting
NCT05383170 2025-11-28
Catalyst
Cytovation AS
Phase 1/2 Completed
NCT04585269 2025-11-25
Bright IDEAS - Young Adults Problem-Solving Skills Training
Rutgers, The State University of New Jersey
Phase NA Active not recruiting
NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT05694013 2025-10-22
ORIGAMA
Hoffmann-La Roche
Phase 2/3 Terminated
NCT02874001 2025-10-06
PO-BADO
Institut Bergonié
Completed
NCT03963518 2025-10-06
SURROGATE-ICI
Institut Bergonié
Completed
NCT03972150 2025-10-06
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT03676218 2025-10-03
DATECANelderly
Institut Bergonié
Completed
NCT03694171 2025-10-03
Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)
Institut Bergonié
Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02674152 2025-10-01
Dose Finding Study of BI 836880 in Patients With Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02689505 2025-10-01
Weekly BI 836880 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT04614662 2025-09-23
Symptom Screening Linked to Care Pathways
The Hospital for Sick Children
Phase NA Completed
NCT05237206 2025-09-18
Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies
Alloplex Biotherapeutics Inc
Phase 1 Completed
NCT02751827 2025-08-24
PreToxE
Institut Bergonié
Completed
NCT04147234 2025-08-19
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT00716417 2025-08-05
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03307629 2025-07-29
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Noxopharm Limited
Phase 1 Completed
NCT01403974 2025-07-25
Phase I Trial of BI 836845 for Various Solid Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT06561217 2025-07-25
Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening
University of Pennsylvania
Completed
NCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT01317420 2025-07-11
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
Boehringer Ingelheim
Phase 1 Completed
NCT03520075 2025-07-03
Study of ASTX029 in Subjects With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1/2 Completed
NCT06926673 2025-07-03
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
GlaxoSmithKline
Phase 2 Completed
NCT02145741 2025-06-19
Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01806129 2025-06-13
EROS
Eastern Cooperative Oncology Group
Phase NA Active not recruiting